We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+23.65%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$5.28B
AUM Growth
+$464M
Cap. Flow
-$292M
Cap. Flow %
-5.53%
Top 10 Hldgs %
49.47%
Holding
185
New
37
Increased
47
Reduced
83
Closed
9

Top Buys

Rank Stock Value
1
VRDN icon
Viridian Therapeutics
VRDN
+$120M
2
FOLD
Amicus Therapeutics
FOLD
+$105M
3
NUVL
Nuvalent
NUVL
+$102M
4
KRYS icon
Krystal Biotech
KRYS
+$86.1M
5
VRTX icon
Vertex Pharmaceuticals
VRTX
+$75.6M

Top Sells

Rank Stock Value
1
AGIO icon
Agios Pharmaceuticals
AGIO
+$149M
2
INCY icon
Incyte
INCY
+$139M
3
AKRO
Akero Therapeutics
AKRO
+$113M
4
IONS icon
Ionis Pharmaceuticals
IONS
+$109M
5
ARGX icon
argenx
ARGX
+$72.3M

Sector Composition

Rank Sector Weight
1 Healthcare 99.71%
2 Technology 0.1%
3 Consumer Discretionary 0.05%
4 Financials 0.03%
5 Communication Services 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PODD icon
26
Insulet
PODD
$11.6B
$53.1M 1.01%
186,699
-25,306
-12% -$7.91M
BDX icon
27
Becton Dickinson
BDX
$42.6B
$51.6M 0.98%
265,662
-31,232
-11% -$5.94M
JBIO
28
Jade Biosciences
JBIO
$1.2B
$51.6M 0.98%
+3,341,103
New +$39.2M
DHR icon
29
Danaher
DHR
$142B
$44.6M 0.84%
194,633
+30,757
+19% +$6.76M
PEN icon
30
Penumbra
PEN
$12.5B
$42.1M 0.8%
135,395
-11,500
-8% -$3.18M
RMD icon
31
ResMed
RMD
$28.8B
$38.8M 0.74%
161,214
-3,620
-2% -$926K
EWTX icon
32
Edgewise Therapeutics
EWTX
$4.18B
$37.9M 0.72%
1,528,518
-1,247,479
-45% -$25M
TMO icon
33
Thermo Fisher Scientific
TMO
$196B
$37.7M 0.71%
65,077
-41,108
-39% -$23.2M
MAZE
34
Maze Therapeutics
MAZE
$1.57B
$36.8M 0.7%
+887,708
New +$30.5M
LLY icon
35
Eli Lilly
LLY
$1.02T
$36.5M 0.69%
34,003
-6,511
-16% -$6.23M
GEHC icon
36
GE HealthCare
GEHC
$28.6B
$34.8M 0.66%
424,514
-38,549
-8% -$3M
TNGX icon
37
Tango Therapeutics
TNGX
$4.48B
$34.8M 0.66%
+3,927,670
New +$33.8M
ABBV icon
38
AbbVie
ABBV
$448B
$30.8M 0.58%
134,859
-36,011
-21% -$8.2M
CI icon
39
Cigna
CI
$75.1B
$30.3M 0.57%
110,013
-12,473
-10% -$3.5M
GKOS icon
40
Glaukos
GKOS
$9.13B
$29.6M 0.56%
261,935
+206,009
+368% +$19.7M
JNJ icon
41
Johnson & Johnson
JNJ
$599B
$26.2M 0.5%
126,800
+51,993
+70% +$10.3M
ANNX icon
42
Annexon
ANNX
$913M
$25.9M 0.49%
5,157,290
– –
STE icon
43
Steris
STE
$20.9B
$25.8M 0.49%
101,705
-16,407
-14% -$4.12M
WVE icon
44
Wave Life Sciences
WVE
$1.1B
$25.3M 0.48%
1,490,518
-2,603,940
-64% -$26.5M
ELV icon
45
Elevance Health
ELV
$82.9B
$24.4M 0.46%
69,645
-35,326
-34% -$11.9M
COO icon
46
Cooper Companies
COO
$14B
$23.9M 0.45%
291,959
-306
-0.1% -$22.9K
GMED icon
47
Globus Medical
GMED
$10.3B
$22.9M 0.43%
262,683
-64,184
-20% -$4.87M
ALGN icon
48
Align Technology
ALGN
$12.5B
$22.1M 0.42%
141,474
-3,202
-2% -$459K
ZBH icon
49
Zimmer Biomet
ZBH
$17.4B
$21.5M 0.41%
238,680
-6,522
-3% -$618K
MCK icon
50
McKesson
MCK
$97.3B
$20.6M 0.39%
25,098
-12,859
-34% -$10.5M
1
2
3 4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q4 2025 Portfolio in Review

As of Q4 2025, Bellevue Group held 185 positions worth $5.28B, up 9.6% from $4.81B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Bellevue Group withdrew a net $292M in Q4 2025, closing 9 positions and reducing 83 holdings. Its most notable exit was Agios Pharmaceuticals, an estimated $149M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Technology and Consumer Discretionary.

Against the trend, Bellevue Group opened a new position in Viridian Therapeutics worth $136M.

  • Bellevue Group's largest Q4 2025 buy was Viridian Therapeutics: 4,358,527 shares worth $136M.
  • Bellevue Group added most to Krystal Biotech in Q4 2025, an estimated $86.1M increase.
  • Bellevue Group's biggest Q4 2025 reduction was Incyte, cutting an estimated $139M.
  • Bellevue Group fully exited Agios Pharmaceuticals in Q4 2025, selling an estimated $149M.
  • Bellevue Group's ten largest holdings make up 49% of its $5.28B portfolio in Q4 2025.
  • Bellevue Group opened 37 new positions and closed 9 in Q4 2025.
  • Bellevue Group's portfolio value rose 9.6% quarter-over-quarter to $5.28B.

Based on Bellevue Group's 13F filing for Q4 2025, filed 17 Feb 2026.